CoChat

Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background: Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification. Methods: Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid. Results: No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these. Conclusions: Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciac453

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Scheme for identifying therapeutically suitable mycobacteriophages. Clinical isolates on slants (top) are cultured in liquid and streaked on solid media to determine colony morphotype and homogeneity. If both smooth and rough colony morphotypes were observed, these are colony purified and subsequently cultured and tested. If the slant appeared homogeneous, the liquid culture was used to screen again a panel of phages, determining the efficiency of plaquing (EOP) on the bacterial isolate relative to Mycobacterium smegmatis (control); each strain was given a GDxx identifier. Phages infecting with an EOP >0.1 were then tested in a killing assay over a range of bacterial phage concentrations and in a survival assay indicating the efficiency of killing and the likelihood of phage resistance emerging. The approximate timeline of screening is shown at left.
Figure 1. Scheme for identifying therapeutically suitable mycobacteriophages. Clinical isolates on slants (top) are cultured in liquid and streaked on solid media to determine colony morphotype and homogeneity. If both smooth and rough colony morphotypes were observed, these are colony purified and subsequently cultured and tested. If the slant appeared homogeneous, the liquid culture was used to screen again a panel of phages, determining the efficiency of plaquing (EOP) on the bacterial isolate relative to Mycobacterium smegmatis (control); each strain was given a GDxx identifier. Phages infecting with an EOP >0.1 were then tested in a killing assay over a range of bacterial phage concentrations and in a survival assay indicating the efficiency of killing and the likelihood of phage resistance emerging. The approximate timeline of screening is shown at left.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Guerrero-Bustamante, 2021, Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse Mycobacterium tuberculosis strains, mBio, 12, e00973-21, 10.1128/mbio.00973-21 · DOI · Paper page

Cited by

Metadata

Authors
Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., Gainey, A., Garcia, C. B., Robert George, C. R., Haidar, G., Ip, W., Iredell, J., Khatami, A., Little, J. S., Malmivaara, K., McMullan, B. J., Michalik, D. E., Moscatelli, A., Nick, J. A., Tupayachi Ortiz, M. G., Polenakovik, H. M., Robinson, P. D., Skurnik, M., Solomon, D. A., Soothill, J., Spencer, H., Wark, P., Worth, A., Schooley, R. T., Benson, C. A., & Hatfull, G. F.
Affiliations
  • University of Pittsburgh (US)
  • Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania , USA
  • UNSW Sydney (AU)
  • Inova Fairfax Hospital , Falls Church, Virginia , USA
  • Johns Hopkins University (US)
  • National Jewish Health (US)
  • Division of Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina , USA
  • Prisma Health (US)
  • Department of Respiratory Disease, Hospital Universitari Vall d’Hebron , Barcelona , Spain
  • New South Wales Health Pathology Microbiology, John Hunter Hospital , New Lambton, New South Wales , Australia
  • Great Ormond Street Hospital (GB)
  • Sydney Children's Hospital (AU)
  • Children's Hospital at Westmead (AU)
  • Brigham and Women's Hospital (US)
  • Miller Children's & Women's Hospital (US)
  • Istituto Giannina Gaslini (IT)
  • Department of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami , Miami, Florida , USA
  • Wright State University (US)
  • University of Helsinki (FI)
  • Hunter Medical Research Institute (AU)
  • University of California San Diego (US)
Corresponding author
Hatfull, Graham F
Venue
Clinical Infectious Diseases
Published
2022-06-09
Volume
76
Issue
1
Pages
103-112
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W4281760779
Cited by
344
References
23
Citations by year
2026: 74 · 2025: 89 · 2024: 91 · 2023: 72 · 2022: 18
FWCI
35.96
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • Howard Hughes Medical Institute (GT12053)
  • Cystic Fibrosis Foundation (HATFUL19GO, NICK20Y2-SVC, NICK20Y2-OUT)
  • National Heart, Lung, and Blood Institute (K08 HL139994-01)
  • Burroughs Wellcome Fund (HL146228, NICK20Y2-SVC and NICK20Y2-OUT)
  • NIH (GM131729, AI154546, R01HL146228)
  • Jane and Aatos Erkko Foundation
Topics
  • Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Keywords
phage therapy, Mycobacterium abscessus, nontuberculous mycobacterial infection, cystic fibrosis, phage resistance, neutralizing antibodies, phage neutralization, compassionate use, adjunctive therapy
MeSH terms
Phage Therapy, Anti-Bacterial Agents, Bacteriophages, Cystic Fibrosis, Pharmaceutical Preparations, Humans, Mycobacterium, Mycobacterium Infections, Nontuberculous, Compassionate Use Trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.